

# Naruto Taira

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9223941/publications.pdf>

Version: 2024-02-01

70  
papers

940  
citations

471061

17  
h-index

500791

28  
g-index

78  
all docs

78  
docs citations

78  
times ranked

1507  
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Controlled Trial of Paper-Based at a Hospital versus Continual Electronic Patient-Reported Outcomes at Home for Metastatic Cancer Patients: Does Electronic Measurement at Home Detect Patients's Health Status in Greater Detail?. <i>Medical Decision Making</i> , 2022, 42, 60-67.	1.2	5
2	Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. <i>Breast Cancer</i> , 2022, 29, 131-143.	1.3	1
3	Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial. <i>Quality of Life Research</i> , 2022, 31, 1829-1836.	1.5	3
4	Abstract PD13-09: Primary analysis from NEOS trial: A randomized phase III study that assessed the long-term prognosis of estrogen receptor positive (ER+) primary breast cancer (PBC) pts who received neoadjuvant endocrine therapy (NET) with/without adjuvant chemotherapy (CT). <i>Cancer Research</i> , 2022, 82, PD13-09-PD13-09.	0.4	0
5	Abstract OT1-12-08: Randomized study comparing electronic patient reported outcomes (ePROs) monitoring with routine follow up during trastuzumab deruxtecan treatment in patients with inoperable or metastatic breast cancer (PRO-DUCE study). <i>Cancer Research</i> , 2022, 82, OT1-12-08-OT1-12-08.	0.4	0
6	Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial. <i>Clinical Drug Investigation</i> , 2022, 42, 253-262.	1.1	0
7	Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 636-649.	5.1	5
8	Older patients' experience of living with cognitive impairment related to hormone therapy for breast cancer: A qualitative study. <i>European Journal of Oncology Nursing</i> , 2022, 57, 102115.	0.9	2
9	Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIIOUS). <i>Cancer Science</i> , 2022, 113, 3169-3179.	1.7	8
10	Effect of isoflavones on breast cancer cell development and their impact on breast cancer treatments. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 307-316.	1.1	10
11	Clinicopathological characteristics, practical treatments, prognosis, and clinical issues of older breast cancer patients in Japan. <i>Breast Cancer</i> , 2021, 28, 1-8.	1.3	11
12	Relationships of physical and breast cancer phenotypes with three single-nucleotide polymorphisms (rs2046210, rs3757318, and rs3803662) associated with breast cancer risk in Japanese women. <i>Breast Cancer</i> , 2021, 28, 478-487.	1.3	2
13	Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. <i>Breast</i> , 2021, 55, 63-68.	0.9	9
14	A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study. <i>Clinical Breast Cancer</i> , 2021, 21, 450-457.	1.1	0
15	Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study. <i>Breast</i> , 2021, 56, 70-77.	0.9	9
16	A Multicenter Study of Docetaxel at a Dose of 100 mg/m <sup>2</sup> in Japanese Patients with Advanced or Recurrent Breast Cancer. <i>Internal Medicine</i> , 2021, 60, 1183-1190.	0.3	2
17	Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 675-683.	1.1	5
18	Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2452-2462.	0.8	16

#	ARTICLE	IF	CITATIONS
19	Systemic therapy and prognosis of older patients with stage II/III breast cancer: A large-scale analysis of the Japanese Breast Cancer Registry. <i>European Journal of Cancer</i> , 2021, 154, 157-166.	1.3	7
20	YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12809.	1.8	6
21	Optimizing the timing of 3.6 mg Pegfilgrastim Administration for Dose-Dense Chemotherapy in Japanese Patients with Breast Cancer. <i>Acta Medica Okayama</i> , 2021, 75, 357-362.	0.1	0
22	Influence of breast density on breast cancer risk: a case control study in Japanese women. <i>Breast Cancer</i> , 2020, 27, 277-283.	1.3	16
23	Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 117-124.e4.	1.1	3
24	Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 354.	1.0	16
25	Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. <i>Journal of Clinical Oncology</i> , 2020, 38, 3743-3752.	0.8	50
26	The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs. <i>Breast Cancer</i> , 2020, 27, 973-981.	1.3	4
27	Desmoid-type fibromatosis of the breast mimicking cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1084-1085.	0.6	0
28	Response Shift—Adjusted Treatment Effect on Health-Related Quality of Life in a Randomized Controlled Trial of Taxane Versus S-1 for Metastatic Breast Cancer: Structural Equation Modeling. <i>Value in Health</i> , 2020, 23, 768-774.	0.1	6
29	Evaluation of Prognosis of Juvenile Differentiated Thyroid Carcinoma. <i>Acta Medica Okayama</i> , 2020, 74, 401-406.	0.1	0
30	A single-nucleotide polymorphism in a gene modulating glucocorticoid sensitivity is associated with the decline in total lung capacity after lung transplantation. <i>Surgery Today</i> , 2019, 49, 268-274.	0.7	5
31	Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 123-133.	1.1	77
32	Randomized, optimal dose-finding, phase II study of tri-weekly nab-paclitaxel in patients with metastatic breast cancer (ABROAD).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1070-1070.	0.8	8
33	The influences of preoperative metformin on immunological factors in early breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14182-e14182.	0.8	0
34	Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan. <i>Breast Cancer</i> , 2018, 25, 60-67.	1.3	3
35	Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study. <i>Pharmacoeconomics</i> , 2018, 36, 215-223.	1.7	21
36	Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 39-47.	1.1	28

#	ARTICLE	IF	CITATIONS
37	A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 855-859.	0.6	6
38	The efficacy and feasibility of dose-dense sequential chemotherapy for Japanese patients with breast cancer. <i>Breast Cancer</i> , 2018, 25, 717-722.	1.3	3
39	Evaluation of trastuzumab without chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients: Randomized controlled trial (RESPECT).. <i>Journal of Clinical Oncology</i> , 2018, 36, 510-510.	0.8	18
40	N-acetyltransferase 2 polymorphism and breast cancer risk with smoking: a case control study in Japanese women. <i>Breast Cancer</i> , 2017, 24, 254-262.	1.3	4
41	Development of a Japanese version of the BREAST-Q and the traditional psychometric test of the mastectomy module for the assessment of HRQOL and patient satisfaction following breast surgery. <i>Breast Cancer</i> , 2017, 24, 288-298.	1.3	17
42	Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers. <i>Oncotarget</i> , 2017, 8, 26122-26128.	0.8	19
43	Breast Cancer Metastasis to the Stomach That Was Diagnosed after Endoscopic Submucosal Dissection. <i>Case Reports in Gastrointestinal Medicine</i> , 2016, 2016, 1-5.	0.2	8
44	A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 289-294.	1.1	7
45	Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 95-100.e1.	1.1	9
46	The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2015 edition. <i>Breast Cancer</i> , 2016, 23, 343-356.	1.3	17
47	PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS636-TPS636.	0.8	0
48	Biomarker analysis of S-1 in SELECT-BC: A randomized phase III study of taxane versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT-BC EURECA).. <i>Journal of Clinical Oncology</i> , 2016, 34, e23274-e23274.	0.8	0
49	The Japanese Breast Cancer Society clinical practice guideline for epidemiology and prevention of breast cancer. <i>Breast Cancer</i> , 2015, 22, 16-27.	1.3	10
50	Impact of modifiable lifestyle factors on outcomes after breast cancer diagnosis: the Setouchi Breast Cancer Cohort Study. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 600-2.	0.6	4
51	Safety and efficacy of gemcitabine and trastuzumab in HER2-directed therapy pretreated patients with HER2-positive metastatic breast cancer: SBP-01 study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 142-142.	0.8	1
52	Impact of preservation of the intercostobrachial nerve during axillary dissection on sensory change and health-related quality of life 2Âyears after breast cancer surgery. <i>Breast Cancer</i> , 2014, 21, 183-190.	1.3	22
53	Utility of the Singapore nomogram for predicting recurrence-free survival in Japanese women with breast phyllodes tumours. <i>Journal of Clinical Pathology</i> , 2014, 67, 748-750.	1.0	23
54	Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 155-164.	1.1	21

#	ARTICLE	IF	CITATIONS
55	A Case of Carcinoma Showing Thymus-Like Differentiation with a Rapidly Lethal Course. Case Reports in Oncology, 2014, 7, 840-844.	0.3	3
56	Bevacizumab plus paclitaxel optimization study with interventional maintenance endocrine therapy in advanced or metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 (BOOSTER) trial.. Journal of Clinical Oncology, 2014, 32, TPS657-TPS657.	0.8	1
57	Effects of lifestyle and single nucleotide polymorphisms on breast cancer risk: a case-control study in Japanese women. BMC Cancer, 2013, 13, 565.	1.1	37
58	Cost-Effectiveness Analysis of Bevacizumab in Combined Chemotherapy for Human epidermal growth factor receptor 2-negative Metastatic Breast Cancer in Japan. Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku, 2013, 18, 1-12.	0.0	2
59	N-SAS BC06: A phase III study of adjuvant endocrine therapy with or without chemotherapy for postmenopausal breast cancer patients who responded to neoadjuvant letrozole (LET): The New Primary Endocrine-Therapy Origination Study (NEOS).. Journal of Clinical Oncology, 2013, 31, TPS654-TPS654.	0.8	0
60	Analysis of health-related quality of life during neoadjuvant endocrine therapy with letrozole in postmenopausal breast cancer patients: N-SAS BC06 trial.. Journal of Clinical Oncology, 2013, 31, 6588-6588.	0.8	0
61	Association between mammographic breast density and lifestyle in Japanese women. Acta Medica Okayama, 2013, 67, 145-51.	0.1	17
62	Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46 cancer. Cancer Science, 2011, 102, 2038-2042.	1.7	36
63	Associations among baseline variables, treatment-related factors and health-related quality of life 2 years after breast cancer surgery. Breast Cancer Research and Treatment, 2011, 128, 735-747.	1.1	77
64	Evaluation of Trastuzumab Without Chemotherapy as a Post-operative Adjuvant Therapy in HER2-positive Elderly Breast Cancer Patients: Randomized Controlled Trial [RESPECT (N-SAS BC07)]. Japanese Journal of Clinical Oncology, 2011, 41, 709-712.	0.6	38
65	Comprehensive geriatric assessment in elderly breast cancer patients. Breast Cancer, 2010, 17, 183-189.	1.3	22
66	The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. Breast Cancer Research, 2010, 12, R43.	2.2	56
67	Determination of Indication for Sentinel Lymph Node Biopsy in Clinical Node-negative Breast Cancer Using Preoperative 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging. Japanese Journal of Clinical Oncology, 2008, 39, 16-21.	0.6	27
68	Contrast-enhanced CT Evaluation of Clinically and Mammographically Occult Multiple Breast Tumors in Women with Unilateral Early Breast Cancer. Japanese Journal of Clinical Oncology, 2008, 38, 419-425.	0.6	13
69	Phyllodes Tumor of the Breast: Stromal Overgrowth and Histological Classification are Useful Prognosis-predictive Factors for Local Recurrence in Patients with a Positive Surgical Margin. Japanese Journal of Clinical Oncology, 2007, 37, 730-736.	0.6	84
70	A CASE OF BREAST CANCER METASTASIZED TO THE CHOROIDEA OF THE LEFT EYE. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2003, 64, 1082-1085.	0.0	0